Ausbil Investment Management Ltd Boosts Stake in Medpace Holdings, Inc. $MEDP

Ausbil Investment Management Ltd lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 111.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,413 shares of the company’s stock after purchasing an additional 2,852 shares during the quarter. Medpace accounts for approximately 1.7% of Ausbil Investment Management Ltd’s investment portfolio, making the stock its 24th biggest holding. Ausbil Investment Management Ltd’s holdings in Medpace were worth $3,040,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MEDP. Quent Capital LLC purchased a new position in Medpace in the 3rd quarter worth $25,000. Optiver Holding B.V. acquired a new stake in Medpace during the 3rd quarter worth about $27,000. Quarry LP purchased a new stake in Medpace during the 3rd quarter valued at about $35,000. Root Financial Partners LLC purchased a new stake in Medpace during the 3rd quarter valued at about $38,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 20.30% of the stock is currently owned by corporate insiders.

Medpace Trading Down 0.0%

Shares of MEDP stock opened at $466.60 on Friday. The stock has a 50 day moving average of $497.26 and a 200 day moving average of $537.33. The stock has a market cap of $13.24 billion, a P/E ratio of 30.50, a P/E/G ratio of 2.24 and a beta of 1.44. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on MEDP. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Leerink Partners dropped their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a research note on Tuesday, February 10th. Finally, Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective on the stock in a report on Friday, March 6th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.